Corrections
We get things wrong sometimes. When we do, we fix the page and record the fix here, so you can see what changed and when.
Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records)
Our policy
- What counts as a correction. A factual error on a published page. Examples: a wrong number, date, status or citation, a source that breaks our primary-source rule, or a claim a primary source doesn't support.
- How fast. We aim to fix confirmed errors within 1 business day of confirming them.
- How we fix it. The page is corrected in place. A dated note at the bottom of the entry says what changed, for example "Corrected 2026-10-30: …". The same note is listed below. We don't quietly delete errors.
- What isn't listed here. Routine updates aren't corrections and don't appear on this page. These include:
- new studies
- new regulatory decisions
- a sponsor topline later replaced by the published paper. That gets a dated "What changed" note on the entry.
- "Last checked" date changes
- spelling, formatting and layout fixes
- Found an error? Email [email protected] with the page link and, if you can, a primary source. We read every report. If a report leads to a correction, we'll credit you here unless you ask us not to.
Log
Newest first. Dates are US Central time.
| Date corrected | Page | What was wrong | What it says now | Primary source |
|---|---|---|---|---|
| 2026-10-29 | News & Trial Tracker: U28, pasireotide (PASIPHY, NCT05928390) | Listed as an "upcoming primary completion" (est. Oct 29, 2026). Recordati had already reported on May 12, 2026 that the trial met its primary endpoint. | Reported (sponsor topline, May 12, 2026; Level C). Next milestone: Phase 3 plan, which the sponsor says will be finalized by end of 2026. | Recordati Q1 2026 results release, May 12, 2026: https://d2e3isjppdvvam.cloudfront.net/wp-content/uploads/2026/05/12171324/Press-Release_Q1-2026-Results-FINAL.pdf · ClinicalTrials.gov NCT05928390 |
| 2026-10-29 | News & Trial Tracker: U08, retatrutide | Listed as "BLA planned / BLA submission to FDA". In an Oct 2, 2026 letter, FDA concluded retatrutide is not a biological product. | Marketing application expected under section 505 of the FD&C Act (a new drug application). Lilly's own guidance for a Q1 2027 filing is unchanged. | FDA letter, filed Oct 8, 2026 in 7th Cir. No. 26-1301: https://storage.courtlistener.com/recap/gov.uscourts.ca7.55916/gov.uscourts.ca7.55916.46.2.pdf · Lilly Q2 2026 release (Aug 5, 2026) |
| 2026-10-29 | News & Trial Tracker: U09, orforglipron (Foundayo) in type 2 diabetes | The cited source was a news aggregator, which breaks our primary-source rule. | Same status, now cited to Lilly's Q2 2026 release. The EU CHMP positive opinion (Oct 15, 2026) is added as a separate event. | Lilly Q2 2026 release: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full · EMA: https://www.ema.europa.eu/en/medicines/human/EPAR/foundayo |
| 2026-10-29 | News & Trial Tracker: U25, setmelanotide in Prader-Willi syndrome (NCT06772597) | Shown only as an upcoming primary completion. It left out that Rhythm had already reported 6-month interim results (n=17) on Jun 13, 2026. | Adds "interim data reported Jun 13, 2026 (sponsor; ENDO 2026)". | Rhythm Pharmaceuticals 8-K, Ex. 99.1: https://www.sec.gov/Archives/edgar/data/1649904/000162828026043170/ex991rytmprpwsatendo2026.htm |
This page will list every factual correction from launch onward. If a page has no entry here, we haven't found or been told of an error on it.